Literature DB >> 22338057

Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema.

Cesar A Moran1, Annikka Weissferdt, Neda Kalhor, Luisa M Solis, Carmen Behrens, Ivan I Wistuba, Saul Suster.   

Abstract

We describe 250 cases of thymoma with emphasis on World Health Organization (WHO) histologic subtyping. The patients were 120 males and 130 females between the ages of 13 and 92 years. Surgical resection was performed, and histologic material was evaluated in every case. Macroscopically, the tumors varied in size from 3 to 20 cm in greatest diameter; about 12% were encapsulated, and about 88% were invasive tumors. A minimum of 5 sections of tumor was evaluated. Histologically, following the schema proposed by the WHO, 21.6% of thymomas were type A, 1.23% type B1, 3.2% type B2, and 9.2% type B3. More than 50% of tumors after subtyping fell into the mixed categories, which, in essence, diminishes the clinical impact of histologic subtyping over staging. The study herein described highlights that all thymomas had the potential to become invasive tumors.

Entities:  

Mesh:

Year:  2012        PMID: 22338057     DOI: 10.1309/AJCP76KEGWQKWOKA

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  16 in total

Review 1.  The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

Authors:  Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

2.  Pathologic Finding of Thymic Carcinoma Accompanied by Myasthenia Gravis.

Authors:  Se Hoon Kim; Im Suk Koh; Yang Ki Minn
Journal:  J Clin Neurol       Date:  2015-08-21       Impact factor: 3.077

Review 3.  Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.

Authors:  Elizabeth A Lippner; David B Lewis; William H Robinson; Tamiko R Katsumoto
Journal:  Curr Treat Options Oncol       Date:  2019-06-22

4.  The impact of neoadjuvant chemotherapy on the histopathological assessment of thymomas: a clinicopathological correlation of 28 cases treated with a similar regimen.

Authors:  Annikka Weissferdt; Cesar A Moran
Journal:  Lung       Date:  2013-05-08       Impact factor: 2.584

5.  Author Reply.

Authors:  Selim Bakan
Journal:  Diagn Interv Radiol       Date:  2017 Jul-Aug       Impact factor: 2.630

6.  Mediastinal type B3 thymoma combined with germ cell tumor: cytologic diagnosis.

Authors:  Xiang-Lan Zhu; Gan-Di Li; Jin-Nan Li; Yong Jiang; Wei-Ping Liu; Xue-Ying Su
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

7.  Volume-based quantification using dual-energy computed tomography in the differentiation of thymic epithelial tumours: an initial experience.

Authors:  Suyon Chang; Jin Hur; Dong Jin Im; Young Joo Suh; Yoo Jin Hong; Hye-Jeong Lee; Young Jin Kim; Kyunghwa Han; Dae Joon Kim; Chang Young Lee; Ha Young Shin; Byoung Wook Choi
Journal:  Eur Radiol       Date:  2016-08-23       Impact factor: 5.315

Review 8.  Expression of cell cycle and apoptosis regulators in thymus and thymic epithelial tumors.

Authors:  Alexandra Papoudou-Bai; Alexandra Barbouti; Vassiliki Galani; Kalliopi Stefanaki; Dimitra Rontogianni; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2015-03-21       Impact factor: 3.984

9.  FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies.

Authors:  Marcelo F K Benveniste; Cesar A Moran; Osama Mawlawi; Patricia S Fox; Stephen G Swisher; Reginald F Munden; Edith M Marom
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

10.  Patterns of metastasis and recurrence in thymic epithelial tumours: longitudinal imaging review in correlation with histological subtypes.

Authors:  A Khandelwal; L M Sholl; T Araki; N H Ramaiya; H Hatabu; M Nishino
Journal:  Clin Radiol       Date:  2016-06-03       Impact factor: 2.350

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.